Qelbree Hits Shelves; Schizophrenia-Related Cognitive Impairment Breakthrough

News

The newly approved viloxazine extended-release capsules (Qelbree), a new selective norepinephrine reuptake inhibitor for the treatment of attention-deficit hyperactivity disorder in patients ages 6 to 17, is now available in the U.S., Supernus Pharmaceuticals announced.

Mothers with depression or a history of depression had poorer-quality relationships with their newborns. (ScienceDaily)

The FDA granted breakthrough therapy designation to the investigational novel glycine transporter-1 inhibitor, BI 425809, for the treatment of cognitive impairment associated with schizophrenia, based on the CONNEX phase III clinical program, Boehringer Ingelheim announced.

The agency also granted breakthrough device designation to Woebot Health’s digital 8-week therapeutic, WB001, for the treatment of postpartum depression.

Latinx young adults may experience more heart-focused anxiety symptoms, such as a racing heart. “This population also struggles with a lot of chronic physical health co-morbidities including heart disease and obesity, so this research is a good fit for a population who tends to blame mental health issues on physical ailments, which generates greater mental health risk,” said study author Michael Zvolensky, PhD, of the University of Houston, in a statement. He was recently awarded a $2.7 million NIH grant to develop a behavioral healthcare app — EASE (Easing Anxiety Sensitivity for Everyone) — aimed at addressing COVID-related health disparities in racial and ethnic groups. (Journal of Racial and Ethnic Health Disparities)

A new guide for pediatricians outlined the signs and symptoms to look for when identifying psychosis in adolescents. (Pediatrics)

Children with autism whose parents were separated often got a very delayed diagnosis — on average 16 months later — according to a new study. (Autism: The International Journal of Research and Practice)

Adamis Pharmaceuticals resubmitted its new drug application to the FDA for the company’s high-dose naloxone injectable, ZIMHI, for opioid overdose treatment.

  • author['full_name']

    Kristen Monaco is a staff writer, focusing on endocrinology, psychiatry, and dermatology news. Based out of the New York City office, she’s worked at the company for nearly five years.

Products You May Like

Articles You May Like

Astepro Nasal Antihistamine Spray Is Approved to Be Sold Without a Prescription
Trialling a new way to boost CAR T-cell therapy
A healthy diet during pregnancy affects outcomes
Bosses should mandate Covid vaccinations for workers, national staffing firm CEO says
Does Grandma Need Surgery for That Broken Wrist?

Leave a Reply

Your email address will not be published. Required fields are marked *